<SEC-DOCUMENT>0001628280-17-008335.txt : 20170808
<SEC-HEADER>0001628280-17-008335.hdr.sgml : 20170808
<ACCEPTANCE-DATETIME>20170808162328
ACCESSION NUMBER:		0001628280-17-008335
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170808
DATE AS OF CHANGE:		20170808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		171015111

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ptgx8-kq22017er.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7B8D6CF046257F80C4779A74C5881835"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:641px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:641px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): August 8, 2017</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:631px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:193px;"></td><td style="width:245px;"></td><td style="width:193px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-37852</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98-0505495</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Commission</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(IRS Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Protagonist Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7707 Gateway Blvd., Suite 140</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Newark, California 94560-1160</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices, including zip code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(510) 474-0170</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:35.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-top:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.02. Results of Operations and Financial Condition.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 8, 2017, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June&#160;30, 2017. A copy of the press release titled &#8220;Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights,&#8221; is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9.01. Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release, dated August&#160;8, 2017, titled &#8220;Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights.&#8221;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this report, including the exhibit hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section&#160;11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:7%;"></td><td style="width:20%;"></td><td style="width:5%;"></td><td style="width:21%;"></td><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Protagonist Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 8, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Thomas P. O&#8217;Neil</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thomas P. O&#8217;Neil</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO EXHIBITS</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release, dated August 8, 2017, titled &#8220;Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights.&#8221;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptgx8-kq2ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s79CEEEC983FE0C00F9EBBE4FC1762580"></a></div><div></div><div><br></div><div style="line-height:130%;text-align:right;"><img src="ptgx8kq2ex991image1.jpg" alt="ptgx8kq2ex991image1.jpg" style="height:45px;width:172px;"></div><div style="line-height:130%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Worldwide co-development agreement with Janssen for PTG-200 brings $50M upfront and potentially up to $940M in milestones</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Q2 cash balance of $64.5M - Cash to middle of 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Newark, California (August 8, 2017)</font><font style="font-family:inherit;font-size:12pt;">: Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the second quarter and six months ended June 30, 2017.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Protagonist achieved several significant milestones during the second quarter, most notably the signing of a major license and collaboration agreement with Janssen for PTG-200, our pre-clinical stage oral interleukin-23 receptor (IL-23R) antagonist for inflammatory bowel diseases (IBD),&#8221; said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. &#8220;In addition to the strategic advantages this major partnership provides us, it has also extended our financial runway, enabling us to advance our clinical pipeline of innovative peptide drugs and expand the utility of our technology platform.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pipeline Highlights:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PTG-200:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist granted Janssen exclusive, worldwide rights to PTG-200, a first-in-class oral peptide IL-23R antagonist currently in pre-clinical development and expected to enter phase 1 studies in the second half of 2017.  The terms of the agreement included a $50.0 million upfront payment, which we expect to receive in the third quarter of 2017.  Protagonist can also potentially receive up to an additional $940.0 million in clinical development, regulatory approval, and sales milestones. Protagonist and Janssen will co-develop and co-fund PTG-200 through Phase 2 clinical development. Protagonist will receive double-digit tiered royalties on future net sales and retains the option to co-detail PTG-200 in the United States, if PTG-200 receives regulatory approval. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A new U.S. patent, No. 9,624,268, providing composition of matter protection for PTG-200 and covering the use of oral peptide inhibitors of IL-23R to treat IBD, was issued</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist was awarded a Phase 2 Small Business Innovation Research Grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.  This grant provides up to $1.3 million of funding over two years to support the </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:24px;text-align:left;"><font style="font-family:inherit;font-size:12pt;">development of biomarkers useful in the clinical development of anti-IL23R agents for the treatment of IBD, including PTG-200.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PTG-100</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The company is advancing the clinical proof-of-concept and dose optimization global Phase 2b trial in ulcerative colitis (UC) patients with alpha-4-beta-7 integrin specific antagonist peptide PTG-100. &#160; PTG-100 is being developed as a potential oral targeted therapy for IBD and related indications.  Based on current enrollment rates, the interim analysis is now expected in early 2018; top-line results are still anticipated for the second half of 2018.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PTG-300</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist has initiated a Phase 1 clinical study of PTG-300, an injectable hepcidin mimetic peptide discovered using the company's proprietary technology platform, in normal healthy volunteers.&#160; PTG-300 is being developed as a potential treatment for patients with chronic iron overload in rare diseases such as beta-thalassemia.  The Phase 1 single ascending dose study is evaluating the safety, tolerability, and pharmacokinetics of PTG-300 in normal healthy volunteers. In addition, the effect of PTG-300 on baseline serum iron levels will be analyzed to evaluate pharmacodynamics-based clinical proof-of-concept. The results of this study are anticipated in the second half of 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Corporate Highlights:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#26282a;">The company appointed Rusty Williams, M.D., Ph.D., current </font><font style="font-family:inherit;font-size:12pt;">President and Chief Executive Officer of Five Prime Therapeutics, to the Protagonist Board of Directors.  Dr. Williams is a member of the National Academy of Sciences and an industry veteran having served in critical roles at various companies such as Chiron Corporation, COR Therapeutics, and Daiichi Research Center.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial Results</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist reported a net loss attributable to common stockholders of $15.0 million and $29.1 million, respectively,&#160;for the second quarter and first six months of 2017, as compared to a net loss attributable to common stockholders of&#160;$7.3 million&#160;and $19.1 million, respectively, for the same periods of 2016.  The increase in net loss for both the second quarter and year-to-date periods were driven primarily by research and development (R&amp;D) expenses related to the accelerated progression to Phase 1 initiation of PTG-300; PTG-100 clinical trial and development activities;  and other pre-clinical studies and discovery research efforts in support of Protagonist&#8217;s pipeline; as well as general and administrative (G&amp;A) expenses for operations.  The net loss for the second quarter and first six months of 2017 includes non-cash stock-based compensation of $1.0 million and $1.8 million, respectively, as compared to $0.1 million&#160;and $0.2 million, respectively, for the same periods of 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">R&amp;D expenses for the second quarter and first six months of 2017 were&#160;$12.0 million and $23.3 million, respectively, as compared to&#160;$5.7 million&#160;and $11.3 million, respectively, for the same periods of 2016.  The increases in R&amp;D expenses were primarily due to increased PTG-100 clinical trial and development activities, which included Phase 2 clinical trial site start-up activities, contract manufacturing costs, and pre-clinical and clinical development studies for other product candidates, including PTG-300.  R&amp;D expenses for the second quarter and year-to-date periods also included an increase in employee-related expenses due to an increase in R&amp;D personnel. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">G&amp;A expenses for the second quarter and first six months of 2017 were&#160;$3.1 million and $6.1 million, respectively, as compared to&#160;$1.4 million&#160;and $2.8 million, respectively, for the same periods of 2016. The increases in G&amp;A expenses were primarily due to an increase in employee-related expenses primarily due to an increase in headcount to support the growth of our operations, consulting and professional service fees, and other administrative expenses.      </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist ended the second quarter with&#160;$64.5 million&#160;in cash, cash equivalents and investments.  With the additional funding from the Janssen collaboration, including the $50.0 million upfront milestone payment the company expects to receive in the third quarter of 2017, the company expects to have sufficient financial resources to fund operations until the middle of 2019.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Protagonist Therapeutics</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Protagonist's initial lead peptide product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), consisting primarily of ulcerative colitis and Crohn's disease.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PTG-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global Phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis.  PTG-200, a first-in-class oral Interleukin-23 receptor antagonist for potential treatment of IBD, initially Crohn&#8217;s disease, is currently in pre-clinical development and is expected to enter a Phase 1 clinical study in the second half of 2017. The company recently announced it has entered into a worldwide collaboration with Janssen Biotech to co-develop and commercialize PTG-200 for all indications, including IBD.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to PTG-100 and PTG-200, the company is developing an injectable hepcidin mimetic PTG-300 as a potential orphan drug for the treatment of rare diseases such as beta-thalassemia.  PTG-300 is currently being studied in a Phase 1 clinical trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protagonist is headquartered in Newark, California with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cautionary Note on Forward-Looking Statements</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs, our collaborations, the initiation and availability of results of our clinical trials, enrollment in our clinical trials, contract manufacturing, capital resources, the possibility of obtaining orphan drug designation, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; or the negative or plural of these words or similar expressions.&#160;&#160;Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses, our reliance on third parties and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates.&#160;&#160;We discuss many of these risks in greater detail under the heading &#8220;Risk Factors&#8221; contained in our quarterly report on Form 10-Q for the quarter ended June 30, 2017, to be filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC. </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Condensed Consolidated Statements of Operations </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(Unaudited) </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(In thousands, except share and per share data) </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:621px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:280px;"></td><td style="width:9px;"></td><td style="width:65px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:6px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Three Months Ended <br>June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Six Months Ended <br>June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,696</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,289</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,321</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,810</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,091</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,404</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Change in fair value of redeemable convertible preferred stock tranche and warrant liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,719</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Other expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,098</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,080</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,323</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,080</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net loss per share attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56.90</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,875,627</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383,910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,821,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,855</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC. </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Selected Condensed Consolidated Balance Sheet Data </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:623px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:370px;"></td><td style="width:17px;"></td><td style="width:14px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:9px;"></td><td style="width:16px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:16px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Consolidated Balance Sheet Data:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cash, cash equivalents and available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,809</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,673</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,593</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,030</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">###</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contact:</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Joan Kureczka, Kureczka/Martin Associates</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel: +1 415-821-2413</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mobile: +1 415-690-0210</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: Joan@Kureczka-martin.com</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For Investors:</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Trout Group</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Marcy Nanus</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel: +1 646-378-2927</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: mnanus@troutgroup.com</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ptgx8kq2ex991image1.jpg
<TEXT>
begin 644 ptgx8kq2ex991image1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'H!U,# 2(  A$! Q$!_\0
M'  !  ,! 0$! 0            8'" 4$ P$"_\0 6A   0," @0&"0T-!P0"
M P$!  $" P0%!A$'$B$Q$T%187&!""(V-W21H;&R%!<C,D)28G)S=;/!T146
M-4-55H*2DY2BPM(8)#,T8Z3P1%-4X</3)4:$@_'_Q  : 0$  P$! 0
M        ! 4& P(!_\0 .!$!  (! @0#!0<#!0 # 0    $" P01!1(A,4%1
M<1,B,C,T88&1H;'!T11"\!4D)5+A(W+Q0__:  P# 0 "$0,1 #\ O\
M
M
M
M
M
M                            /E/414L#YIY611,3-SWKDB'R9VZR1$S.
MT/J#GV^]VVYN<RCK(Y7M3-6IL7+H4Z!\K:MHWK.[U:MJSM:-I  >GD
M          !Q,0XNL.%F1NO5UIZ-9/:,>N;W)RHU,U5.?(]=FO=MQ!;V5]JK
M8:RE>JHDD2YIFF]%XT7F4#H
M
M
M
M
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M0H^&6#$&*Z=$<W)]-;I&[EXG2IYF^/D+]
M
M
M
M
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M_P#09! &PHM,^ )456XAC3+WU-,WSL0Z%+I.P569)%B>VMS1%]FF2/TLC%H
MWI0W.@N3->AKJ:J9[Z"5KT\BJ>LP'%+)!(V2*1\<C5S:YBY*G0I,;'I7QI87
M-2GOM341)OBK%X9JIR=MFJ)T*@&RP4/AKLCZ:9[(<2VE:=5V+4T2JYB=+';4
M3H5>@N6QX@M.(Z%*VT7""MIUWNB=M:O(Y-[5YE1% Z8
M                                  %?W'31@JUW*KM]5<)FU-+,^"5J
M4TBHCVJK53-$V[44"P 5MZ^V ORE/^Z2?8>NUZ9,&7BZ4MMH[A,^JJI6Q1-6
MF>B*Y5R3:J9(!/@
M
M            S)C_ $LXULN.[S;+=>N!I*>H5D4?J6%VJF2<:L55ZU--F,=*
MO?/Q#X6OF0#H>O=I"_+Z?N4'] ]>[2%^7T_<H/Z"O@!L+1!B.Z8HP+'<;Q5^
MJ:Q:B1BR<&UFQ%3),FHB>0GI5V@#O8Q>%R^="T0
M    ! [QIAP=8KM56RNKYF5=,_@Y&)3/<B+THF2@3P%;>OM@+\I3_NDGV'VH
MM-F"*^MIZ."XSNGJ)&Q1M6ED3-SER3;ERJ!88
M         !\Y98X(GRS2,CB8U7/>]<D:B;U5>) /H?Q++'!$^661D<;$UG/>
MN2-3E55W%/8R[("SVATE)AR!+K5MV>J'*K:=J\R[W]62<Y0^*,=XBQ?,KKO<
MI98<\VTS%U(F=#$V=:YKS@:1Q+IRPA8%?#2U+[M5-V:E%M8B\\B]KE\76*GQ
M!V0F*+GKQVF"FM,*[G,3AI<OC.3+Q-0J, =&[7V[7V?AKK<JNMD3<M1*K]7H
MS79U'.  '8MN)[Q:D1M-72<&FZ-_;MZD7=U''.]AW!F(<4R:MFM-35-SR65&
MZL;5YWNR:GC/-J5O&UHW>J7M2=ZSM*24.D^9N3:^WL?RO@=J^1<_.=^DT@6.
MIR1]1)3N7BFC7SIFAT\/]C?7S:DN(+Q#3,V*L%&WA'JG(KG9(B]".+,L>AG!
M-C1KDM+:^9-\M>[A<_T?:?PD._#L%NT;>B?CXIJ*=YW]5>TE?2U[%?2U4,[4
MWK$]'9=.1Z"\H:2GIZ=*>&GBC@1,DC8Q$:G4FPY==A2RU^:R43(WK[N'M%\F
MSQH0\G"K1\%OQ3<?&*S\RNWHJ$$YK]&^]U!79\C)T_F3["+W'#]RM>:U5'(U
MB?C&]LWQIL(&72YL7Q56&'68,O2ENKG  X)+ZT]5/22<)3SR0O\ ?1N5J^0D
M%!CVZTN39W1U3$_[C<G>-/KS(T#ICS9,?P3LY9,&++\==UGVW'EIK<FU&O1R
M+Q2;6_K)]>1)HI8YHVR12-D8Y,T<Q<T7K**/7;[M6VN37HZE\2YYJB+VKNE-
MRECAXI:.F2-U9FX12>N*=O5=P(/9M(,$ZMAND20NW<-&BJU>E-Z>7J)I#-'4
M1-EAD9)&Y,VO8N:+UEKAU&/-&])4V;3Y<$[9(V?0 '9Q
M<7%W<;??F^?Z-QAHW+B[N-OOS?/]&XPT  )KHLPI;\98S9:KFZ=M,L$DBK Y
M&NS1-FU44"% U+_9XP;_ .1=?V[?Z!_9XP;_ .1=?V[?Z ,M U+_ &>,&_\
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M<6)E254B[:AJ)[1R^_1./C3G3:%V
M                &(<>=\+$WSK4_2N-O&(<>=\+$WSK4_2N CQ*=&_?)PY\
MX1>DA%B4Z-^^3ASYPB]) -K
M
M                    !C'2KWS\0^%KYD-G$)NNB7!5ZN=1<KA9>&K*A^O+
M)ZJF;K+RY->B)U(!C8&OO61T>_D#_>S_ -8]9'1[^0/][/\ U@<_0!WL8O"Y
M?.A:)R</8<M>%[8EML]+ZEI$>KTCX1S]J[US<JKY3K
M       #&.E7OGXA\+7S(;.,8Z5>^?B'PM?,@$..SA+NRL?SA!](TXQV<)=V
M5C^<(/I&@;F                              "-8XQG08'P]+=*WMY%[
M2G@1>VFD7<B<B<:KQ(G0BA_6,,:V?!-J6NNL^3G9I# S;),Y.)J=:9KN0RWC
MS2C?<=3NBGD6CM:.SCH87+J\RO79KKT[.1$(_B;$]TQ9>9KI=:A99Y%[5J;&
M1-XFL3B1/_:YJJJ<<    !ZK=;JR[5\-#04TM353.U8XHFYN<H'E)M@S19B3
M&KF34M-ZEMZKMK:E%:Q?BIO?U;.54+BT>Z"+?9V17+%+8Z^OR1S:3?!"OPO?
MK_#T[%+E:UK&-:QJ-:U,D1$R1$Y *QPIH+PMA](YKC&MYK6[5?4MRB1>:/=E
M\;6+,BBC@B9%%&R.-B:K6,3)&IR(G$?0       _%1%3)=J*?H CMUP9:;FC
MGMB]2S+[N%,D7I;N4@UYP=<;2CI49ZIID_&1)M1.=-Z>5.<ML$//H<.7KMM/
MV)VGXAGP]-]X\I4,"S\08*H[HUT]&C:6KW[$R8]>=.+I3RE;UU!46ZI?3U4+
MHI6[T7CYTY4*34:7)@GWNWFO]-K,>HCW>_D^  (R4'3LV(*VR3:U/(JQ*N;X
M7[6NZN)><Y@/5;VI/-6=I>;TK>O+:-X7#8L0T=^I]:%=29J>R0N7:W[4YSL%
M&4=9/05,=13R+'+&N;7(6SAO$$5_H.$R1E3'LFC3B7E3F4OM%K8S>Y?XOU9S
M7:"<'OT^']': !8*T             <7%W<;??F^?Z-QAHW+B[N-OOS?/]&X
MPT +1T =\^+P2;S(5<6CH [Y\7@DWF0#5P          ')O^&K/B:B6DO%N@
MK(>+A&]LSG:Y-K5YT5#K #,&D?0?6X;BFNV'G2U]K9FZ6!VV:G3EV>W:G*FU
M.-%R52GS?YFC3CHTBL-3]\]FA1EOJ9-6J@8F38)%W.3D:[DXEZ41 I<^M/43
M4M1%44\KXIHGH^.1BY*UR+FBHO+F?( ;-T9XU;CC"$%?)JI70KP%8QNS*1$3
MMD3D<BHO6J<1,C*6@?%#K'CMEMEDU:2[-X!R*NQ)4S6->G/-OZ9JT
M                                       &(<>=\+$WSK4_2N-O&(<>
M=\+$WSK4_2N CQ*=&_?)PY\X1>DA%B4Z-^^3ASYPB]) -K
M
M
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MKDXT7:BGT(K@*O6LP_P#US?2O6/]'>GG5.HE1JL.2,F.+QXL?GQ3BR6QSX
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M+FJJ?R!OBCK*>OI(:NDG9/3S,1\<L:YM>U=RHO(?<BNC;O;X<^;XO10E0
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MC1?UE0C=3I7P-2N5LF):)RHN7L6M)Z**8VEFDGE=+-(^21RYN>]<U5>=5/X
MV,FF' 3G(B8B@S5<ML4B?RG5H,?X2N2HVEQ+:WO78C'5+6N7H1RHIB0 ;]8]
MLC&O8Y'-<F:.:N:*A_1A>RXGOF'I4DM-VJZ-<\U;#(J-=TMW+UH6YA/LBJ^G
M?'38IH6U<.Y:NE:C)$YW,]J[JU>L#1@.78<0VK$MM97VBNBJZ9VS6C7:U>1R
M+M:O,J'4       !GG3SBS$%BQM0TEIO-;10/MS)'1P3*Q%<LDB9Y)QY(GB
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M<!76&--6$,2/9 ^K=;*MVQ(J[)B.7F>G:^-47F+#:Y'M1S51S53-%3<H']
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M^H3ED5.+X*;.7/>>/2GI)J,=WG@J=7Q66E<J4T*YIPB[N$>G*O%R)LY<Z_
M  #KVS"U_O#4=;;)<*QB^[@IWN;XT3([\6B/'<S=9N&ZI$SR[=[&KXE<@&G]
M&W>WPY\WQ>BA*B/8&M]3:\#V.AK85AJJ>CCCEC5456N1-J;-A(0!Q<3XJM.$
M;2^XW>J;#$FQC$VOE=[UC>-?^+DFT\V-,9VS!%C?<KB[6<O:P0-7MYG^]3ZU
MXO(9#Q?C"ZXTO4ERNDRKM5(86JNI WWK4\Z\?&!)L?:8;YC-TM'3.=;;.NQ*
M:)_;2I_J.X_BILZ<LRN0  .OA_"]ZQ16^I+-;IZR3W2L3)K.=SEV-3I4N+#_
M &-U1(UDN(;TR'/:M/0LUE_7=L1?T5Z0*&!K6W:"L"4+$26W3UKT]W4U+\_$
MQ6IY#L)HIP,UJ(F&J+)-FU'+]8&,@:]KM"6 ZUJY69:9Z^[IZB1JIU*Y4\A"
M;[V-M*]KI,/WR6)W%#7,1Z*OQVHBHGZ*@9X!)\5:/\28.D__ "]MD93JN3:J
M/MXG?I)N7F7)>8C ';PSBV]81N*5MGK9*=^::\>^.5.1[=RIYN+(TYHXTNVO
M&[64%4C*"](W;3J[M)LMZQJN_EU5VISHBJ9(/[BED@E9+%(^.1CD<Q[%R5JI
MN5%XE WX"G]$&EO[YVML-_EC9=V-R@F79ZJ1$VY\6NF77U*7    %+=DEW'V
MCP__ .-QFDV)I2P%58_LE%04M;#2/IZGAE=*U514U53+9TE5_P!FN[_G#0_L
M7@4>"\/[-=W_ #AH?V+RGKU;'V6^7&UR2-D?154E,Y[4R1RL<K55/$!X #I6
M"SR7^_V^TQ2MBDK9VP-D<F:-5RY9J!S07A_9KN_YPT/[%X_LUW?\X:']B\"C
MP7A_9KN_YPT/[%X_LUW?\X:']B\"CR\.QK[H+YX+'Z8_LUW?\X:']B\GVBO1
M76Z/[E<*NKN5/5I50MC:V)CDU<ESS7,"T0 !RL1U-PH\.7*IM,<4MP@IWR01
MRM5S7N1,]7)%1=N66_>8UQ+C;$6+9M>\72>H9GFV'/5B9T,3).O+,V^8OTFX
M:^]7'UTH&,U:9\G#TV29)P;^V1$Z,U;^B!$ #M6+"5_Q(]&VBSU=8U5RX2.-
M=1%YWKDU.M0.*"X+1V.V*:Q&ON-906YB[VJY99$ZF]K_ !$OH>QKM$:)]T,0
M5U1R^IX60^?7 S@#4T/8\8,B5NO-=9LMZ25#=O3JM0_J;L>L%R^T?<X=F7L=
M0GC[9J@97!H^X]C7:)&K]S+_ %M.[B]4Q,F3^'4*_P 0Z!\866-\])%#=H&I
MG_='>R(GQ'9*J\S<P*P!])H)::9\,\3XI6+JO9(U6N:O(J+N/F!9FCK3%=L'
M2PT%Q=)<+)FC5B<[.2!.6-5XD]ZNSDRWFI+->:"_VJGN5MJ65%)4-UF2,\J*
MG$J;E1=Q@\L71+I'FP1?4I:R1SK)6O1*AB[>!=N25.CCY4YT0#70/Y8]LC&O
M8Y',<F;7-7-%3E0_H    !Y;C<*6U6^HKZZ=D%+3L6261Z[&M0#^;G<Z*SV^
M>ON%3'34D#=:261<D:G_ #9EQF:=(FG"Y8B=+;</.EMUJ7-KI47*:H3G5/:-
MYDV\J[<B/:3-)5;CR[*R-TD%F@<OJ:F5<M;X;^5R^1-B<:K P&\ _N&&2>9D
M,,;Y)7JC6L8F:N7D1$W@?P"U<,:!,4WR-E1<G16:F=DN50BOF5/DTW=#E12S
MK3V/&$Z)&NN%17W"3W2.D2)B]"-VI^L!EP&R*?1#@2F;JLPY3.3_ %)'O7QN
M<I^SZ(\"5#-5^&Z5$_TWO8OC:Y ,; U-=.Q[P?6M<M%)7V]_N>"FUVITH]%5
M?&A7&(^QZQ);&/FLU53W:%NW@T]AF_555:OZV?,!4!:^CC33<\+/AMM[=+<+
M-L:U57.6G3X*K[9OP5ZE3<M8U]OK+75OI*^DGI:F-<G13L5CDZE/,!O*U76B
MO5M@N%NJ8ZFDG;KQRL78J?4O*B[4*<[)3N?L7A4GH%5Z,])5=@*[:KM>>SU#
MT]54V>[BX1G(Y$\:;%XE2RNR$N-)=L'X;KZ"=D])43ODBE9N<BL3Q='$!GH
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M,<T,C=5\<C4<UR<BHNQ4*'TD:!V<'-=\'1JCTS=+;,\T5.-8EY?@KU<2+?H
MP$]CHWN8]JM>U<G-<F2HO(I_)I+35HKCN=)48IL5.C:^)%?6P1I_CL3>]$]^
MF]>5.??FT#Z4\\M+415$$KXIHG(^.1BY.:Y%S147B4UWHGTA,QUAU4JG-;=Z
M+)E4Q-G")Q2(G(NW/D5%XLC(!)<!XNJ,%8KI+M"KEA1>#J8F_C(E]LG3N5.=
M$ VT#X4=7!7T<%92RMEIZB-LL3V[G-5,T5.I3[@   ,0X\[X6)OG6I^E<;>,
M0X\[X6)OG6I^E<!'B4Z-^^3ASYPB])"+$IT;]\G#GSA%Z2 ;6
MK#2IHJET@7*TUE'64]'+3M=#4RRM5RK%GFW51-ZHNML54]MO+/ %;X8T)81P
M[J35%*MVJV[>%K<G,1>:/VOCS7G+%CB9#&V.)C6,:F36M3)$3D1#^P
M  !#L<Z-K'CJC<E9"E/<$;E%71-3A&+Q9^_;S+U*B[3*&+\(W/!=\DM=SCR<
MG;12M]I,SB<U>3S;C<!!]*6!XL;82FACC1;G2-6:B?QZZ)M9T.1,NG)>(#'
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M;E+73-19'<J-]XWF3K5=YT\'X2MV#+!#:K<SM6=M+*J=M,_C>[G\R9)Q'?
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MZJI,U]RJY/:G0JHOZ3B^3%>C>^NP[I LM?K:L7JAL,OQ']H[/H1V?4;4
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M:^9 (<=G"7=E8_G"#Z1IQCLX2[LK'\X0?2- W,
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MJW5D?!U-+*Z&5O(Y%R7J-Z&8.R'L+;=C6ENT3$;'<Z?-^7'+'DUR_JJP"GP
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M$CD]VU/&G/L1 TP#FV6_VK$-$E7:;A3UL"Y9NA?GJ\SDWM7F7)3I
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MVV[7K]2>7H)[:[/0VB'@J.!K,_;/WN=TJ>\%M@TF+#\,=?-3:C69L_QST\@
M$E%                <7%W<;??F^?Z-QAHW+B[N-OOS?/\ 1N,- #T4==5V
MZH2>BJIZ69$5$D@D5CLEXLT7,\X [/WVXD_."Z_ODGVC[[<2?G!=?WR3[3C
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M6I^E<;>,0X\[X6)OG6I^E<!'B4Z-^^3ASYPB])"+$IT;]\G#GSA%Z2 ;6
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M+7S(!#CLX2[LK'\X0?2-.,=G"7=E8_G"#Z1H&Y@
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MF@E9+$],VO8Y%:Y.5%3>3*UK6-JQL@VM:T[VG>7T !Z>0
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MD AQV<)=V5C^<(/I&G&.SA+NRL?SA!](T#<P
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M-RIQ*A[0                   XN+NXV^_-\_T;C#1N7%W<;??F^?Z-QAH
M6CH [Y\7@DWF0JXM'0!WSXO!)O,@&K@                       8(K_PA
M4_*N\ZGG/17_ (0J?E7>=3S@3G0]WUK#\J_Z-QL8QSH>[ZUA^5?]&XV,
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M&8>R/[X%O^:H_I90*>  &Y<(]QMB^;X/HVG:.+A'N-L7S?!]&T[0
M     !P,38-L.+:58;Q;8:AVKJLFRU98_BO3:G1NY44SAI)T-W#!D;[I;9'U
M]E1>V>J>RT_)KHFQ4^$G6B;,]7'\2Q1S1/BEC;)&]JM>QZ9HY%V*BIQH!@,$
MUTJ819@W'-50TS=6AG:E32I[V-RKVO4Y')T(A"@+*T'XG?A_2#3TCWJE)=<J
M21N>S77_  URY=;9T/4UJ8)H*M]!<*6LC_Q*>5LK<N5JHJ>8WL    QCI5[Y
M^(?"U\R&SC&.E7OGXA\+7S(!#CLX2[LK'\X0?2-.,=G"7=E8_G"#Z1H&Y@
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MOM9&IV[4Z6IG^BO*:,,3:/:Y]NTAX>J&N5N5PB8Y4]ZYR-=Y'*;9
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MR<J^'LDNX^T>'_\ QN S2  -;:">]5;_ ):?Z1Q9)6V@GO56_P"6G^D<62
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MZ"Q^"R>F4>7AV2G=!8_!9/3*/ &S=%7>PP]X*GG4QD;-T5=[##W@J>=0)D
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MP_>X;Y;&5#%1)6]K,SWKOL7>A<\+S1M.*>_=1<7PVYHRQV[.L "W4H
M   </%F*;?@_#]3=[B]$CB3)D>?;3/7VK&\Z^1,U78B@9U[(:NBJM(T4$:HK
MJ2ACBDV)FCE<Y^7ZKV^,J8Z%\O-5B"]UMVK7:U15RK*_+<F>Y$YD3)$YD.>
M  $FT>T+[CI#P]3M:KL[A$]R)[UKD<[R-4VR9P[';"<E3>:K%-1'E3TC5IZ9
M53VTKD[94Z&KE^GS&CP                   XN+NXV^_-\_P!&XPT;EQ=W
M&WWYOG^C<8: %HZ .^?%X)-YD*N+1T =\^+P2;S(!JX
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M\U,99[(?OCP_-\7I/ J8  ;NL'<];/!(O10Z)SK!W/6SP2+T4.B
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M2</.J(Z15=EL:F>2=?4ACTO#L:^Z"^>"Q^F!H\
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M_K.GA_1GA+"]S;<K/:?4U8UBL23U1*_8N],G.5/(!+@
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M+8-"V"K YLGW-6X3MVI+7NX7^'8S^$G[&-C8UC&HUC4R:UJ9(B<B ?T
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MB:Y?<R+J+_%D2J:K#?X;0AY-)GQ_%278!_+7(YJ.:J*B[E1=Y_1(1P
M
M
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MQ%Y799<R9KQ&PX88Z>".&&-L<4;48QC4R1K4V(B)R9 ?0
M
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M[  )2(
M
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MWO<O*OD3)-R'=
M
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M !Z>0
M
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M&\)M1;1:8(9LLEG<FO*OZ;LUZDV$D
M
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M3J  #UVNYU%IKHZJG=D]N]J[GIQHO,7#:[E!=K?%60+VKTVMXVKQHO04F2G
M=X6CN?J&1WL%4N29\3^)>O=XBPX?J9QWY)[3^JLXEI8RXYR5CWH_1:  - S8
M
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MM-3:M8VCI^@ "4B
M                                                  <;$]RGM5CF
MJZ96I*US4363--JHAYO>*5FT^#WCI.2\4CO+L@JK[_KS[^#]F33!]XJKU:9J
MBK5BR-G6--5N29(UJ_6I%PZW%FOR5WW2L^@S8*<]]MDA !,0@  "!^N5!^2Y
M/VR?83PH8K>(:C)AY?9SMOO^RTX;IL6?F]I&^VW[K%H=(,-;74U*EN>Q9Y6Q
MHY947+-43/=SDT*5L/X>MGA4?I(74>N'Y\F:LS>=WGB6GQX+UC'&VX "P5H
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MMJ>/,]A%L U"SX:1BK_@RNC3R._F)2:O!?VF*MO.&-U&/V>6U/*0 '5R
M
M                  !'K[A*DOU8RIGJ)HWMC2-$CRRR157C3G.9ZW%M_P#-
MJOX?L)H"/?28;VFUJ]4FFLSTK%:VVB$+];BV_P#FU7\/V#UN+;_YM5_#]A-
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M?-CT7O!_DV]4]T:_Y:X_'9YE)X0/1K_EKC\=GF4GA8Z#Z>O^>*KXC]5?[OT
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M54&LC>'BUEVY:Z9GU14<B*BHJ+QH?-XE]F)A^@ ^O@
M        *NT_N5NC&5$54UJN)%RX]JKM\1E$UIIXIG3Z+*V1NZ">&1W1KHW^
M9#)8      - ]C/ B1XEJ%RS5:9B<J?XBKYT\1GXOSL:*UB3XBH'*FNYL$S$
MXU1%>CO2:!H,                                AND9B+8Z5_&E2B)U
MM=]A,B%Z1YD;:*2'W3Y]=.A&JG\R$76[?T]MTO0;_P!33970 ,RU@     L/
M1NY5M=:SB29%\:?^B;$-T<Q:MEJI<O;U"IXFI]I,C3:+Z>K)Z_ZF^P "4B
M
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MKY'TT;G.5=JJK4S4I0NBQ=S]M\%B]%"'PR]K7MS3NG<7I2M*\L;=71 !<J,
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M]KM"SS:R3563U:ON6\6SEVY]?,3]!JLV6W);K'FKN(Z/!BI[2G2?)*  6RF
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M&KQTBE(K'@QN2\Y+S>?$ ![>
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ML  ]O(          !!=*N!&XYPJZ&G:U+I1YS4;ER3-<MK%7B1R(G6B+Q$Z
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MEH^'WS3%[]*_J_N[W:HO%:^JJ7=LNQK4W,3D0\0!06M-IYI[M)6L5B*UCI
M#X^@  %H8+P^MHMRU,[,JNI1%5%3:QO$WZU_]'%P7A376.Z5\>4:+G!$Y/;+
M[Y>;DY?/89<\.TDU_P#FO'I_*BXGK(M_\..?7^  %NI0
M
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MU(KEPMGJ5XJCMXE7FD1/*Y&EFTE935],RIHZF&I@>F;987H]KNA4V*!]P
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M9Q.;Q-,/2/-^'Z 6JG
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M%Z32?%68\DX[Q>/!0Y,-'ET;#6SV^1V3:A->//WR<76GF.+B:S.LMUDA1J\
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M0K)B!7Y;(H7.5?$GUF=TO345Y?-J-9UTM^;R6D #3LD
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M=Y  >W@
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M%[5.-$.116.Z,K:=SK76-:DC555@=LV]!QOAM3+-:Q.T2[X\];X8M:8WF%R
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MI&R#?+DR3O>9D ![>
M
M                               /Q41R*BHBHO$I^@#R.ME ]<W4-,Y>
M58F_8?6*F@@_PH(X^+M&HGF/L#S%:QUB'V;6GI,@ /3X
M'P?24TCM9]/$]W*YB*?<'R8B>[[$S'9\HJ>&'/@H8V9^]:B'U /L1L^3,SW
M     YU][G[EX++Z*G1.=?>Y^Y>"R^BIXR?!/H]XOF5]5+DST;?YZN^2;YR&
M$ST;?YZN^2;YS.:'ZBK4<0^EO_GBL8 &F91\I*:"9<Y(8WKRN:BGY'301.UH
MX(V+RM:B'V!\Y8[ON\[;;@ /KX        '\N:CFJUR(J+O13^@!XW6N@>N;
MJ&F<O*L3?L/O%300?X4,<?Q&HA]0>8K6.L0]3:T])D !Z>0       'SDABF
M3*6)CT^$U%/X91TS':S*>)J\J,1#[@^<L/N\]MP 'U\          !\^!BSS
MX)F?+JH?0 ;              '\OC9(W5>QKFKQ.3-#^@!XUM=O5V:T%,J[\
M^";]AZ(XHXFZL<;6)R-3(^@/,5B.T/LVM/>0 'I\      _A\;)$R>QKDY')
MF?V /C'2P1+G'!$Q>5K$0^P!\B(CL3,SW  ?0
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M^MO(J>1=@$K
M
M
M  \5VA?46>NAB:KI)*>1C&\JJU41#V@^6CFB8?:SRS$QX*@^\^]_DY_Z[?M)
M1@:R7"U5=6^LI70M?&B-551<USYE)N"#BX?CQ7B\3/189N)9<V.<=HC:0 $]
M7
M                                                   5)C66HDQ'
M5-G5V3,FQHNY&Y;,BVSR5EMHJ]6K5TD,ZMW+(Q%5.LBZO3SGQ\L3LEZ+4QI\
MG/:-U1V>P5MZEU::+V-JY.E?L:WKXUYD+"LN"[;:D;),U*NI3;KR)VJ+S-W>
M/,D,,,5/$V*&)D<;4R:QC41$Z$/H<]/H,>+K;K+KJ>(Y<W2O2'X?H!.5X
M          $#QIHEPUC)))Y*=*&Y.S5*RE:C7.7X;=S^O;SH3P 8UQSHPO\
M@659:N)*JVJ[*.N@3-B\B.3>Q>9=G(JGAT>U=RH\?622T\(M4ZK8S48OMV*J
M(YJ_!5N>?-M-J30Q5$+X9HF2Q2-5KV/:BM<B\2HN]#E6K">'[)5/JK99+?15
M#TR62"!K79<F:)L3F [(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
0                  __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
